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Abstract
The beneficial effect of folic acid supplementation before and shortly after conception is well recognized, whereas
the effect of supplementation during the second and third trimesters is controversial and poorly documented. Our
aims were to systematically review randomized controlled trials (RCTs) investigating the effect of folate
supplementation on birth weight, placental weight and length of gestation and to assess the dose–response
relationship between folate intake (folic acid plus dietary folate) and health outcomes. The MEDLINE, EMBASE and
Cochrane Library CENTRAL databases were searched from inception to February 2010 for RCTs in which folate
intake and health outcomes in pregnancy were investigated. We calculated the overall intake-health regression
coefficient (β^) by using random-effects meta-analysis on a loge-loge scale. Data of 10 studies from 8 RCTs were
analyzed. We found significant dose–response relationship between folate intake and birth weight (P=0.001), the
overall β^ was 0.03 (95% confidence interval (CI): 0.01, 0.05). This relationship indicated 2% increase in birth weight
for every two-fold increase in folate intake. In contrast, we did not find any beneficial effect of folate
supplementation on placental weight or on length of gestation. There is a paucity of well-conducted RCTs
investigating the effect of folate supplementation on health outcomes in pregnancy. The dose–response
methodology outlined in the present systematic review may be useful for designing clinical studies on folate
supplementation and for developing recommendations for pregnant women.
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Introduction
Folate plays a crucial role in the one-carbon metabolism
for physiological nucleic acid synthesis and cell division,
regulation of gene expression, amino acid metabolism
and neurotransmitter synthesis [1]. During pregnancy,
increased folate intake is required for rapid cell prolif-
eration and tissue growth of the uterus and the placenta,
growth of the fetus and expansion of the maternal blood
volume [2]. Folate requirements are 5- to 10-fold higher
in pregnant than in non-pregnant women [3], therefore
pregnant women may be at risk for folate deficiency.
The importance of adequate periconceptional folate
supply is well recognized in human health; the link be-
tween maternal folate status and fetal neural tube
defects (NTDs) [4,5] and other congenital malformations
[6-10] is generally accepted. In most countries women
are advised to use folic acid supplements in the pericon-
ceptional period: 0.4 mg per day when planning a preg-
nancy, or 4 mg per day when a previous pregnancy was
affected by NTD [11].
However, the effect of folate supplementation through-
out pregnancy on several other health outcomes is
highly controversial [12]. Numerous observational stud-
ies suggest a potential benefit of good maternal folate
status on birth weight, placental weight or length of ges-
tation [13-18]. In contrast, supplementation trials have
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shown equivocal results: some supplementation trials
reported no effect [19-24] whereas other trials reported
significant beneficial effect of folate supplementation on
at least one of the above-mentioned pregnancy out-
comes [25-28].
The aims of this systematic review and meta-analysis
were to summarize the evidence from randomized con-
trolled trials (RCTs) and to assess the dose–response re-
lationship between folate intake and birth weight,
placental weight as well as length of gestation.
Methods
The research presented here is part of a project within
the European Micronutrient Recommendations Aligned
(EURRECA) network that aims to identify micronutrient
requirements for optimal health in European popula-
tions (www.eurreca.org). Data reported in this systematic
review represent part of a wider review process aimed to
identify studies assessing the effect of folate intake on
different markers of folate status and health outcomes in
different population subsets with potential folate
deficiency.
Search strategy
Electronic searches were carried out in Ovid MEDLINE
(www.ovid.com), EMBASE (Ovid) (www.ovid.com) and
the Cochrane Library CENTRAL database (www.
thecochranelibrary.com) from inception to February
2010. Text terms with appropriate truncation and index-
ing terms were used to identify articles eligible for re-
view. The general search strategy was in the following
form: [randomized controlled trials] AND [human stud-
ies] AND [intake or status] AND [folate or folic acid or
vitamin B9]. The search strategy was adapted to each of
the individual databases. The electronic searches were
supplemented with hand searches of journals, and the
reference lists from relevant articles located were used
to identify additional sources. We did not apply any lan-
guage restriction.
Inclusion criteria
To be included, a study needed to meet the following
criteria: 1. supplementation study in healthy pregnant
women, 2. RCT with control group which received pla-
cebo or no treatment (in the case of combined interven-
tion with other micronutrients the only difference
between intervention and control group is folate supple-
mentation), 3. minimum duration of supplementation of
12 weeks, 4. report folate intake from supplements, forti-
fied foods or natural food sources, and 5. report one or
more of the following health outcomes: birth weight,
placental weight and length of gestation. Only papers
meeting all inclusion criteria were included in the
review.
Data collection and extraction
Titles and abstracts were screened for inclusion by two
independent reviewers, with duplicate assessment of a
random sample of 10% in order to harmonize the
process. The full text of the potentially relevant titles
and abstracts was screened for inclusion by using an in-
clusion/exclusion form. Included papers were extracted
into a Microsoft Access 2003 database file (Microsoft
Corp, Redmond, WA) by two independent reviewers.
The database included bibliographic and methodological
details, population characteristics, intervention details as
well as outcome data. In doubtful cases, studies were
discussed within the review team before beginning full
data extraction.
Assessment of internal validity of included studies
In order to assess the risk of bias in the studies, the fol-
lowing indicators of internal validity specific to the RCT
methodology were collected: 1. method of sequence
generation and allocation, 2. blinding of participants,
3. number of participants at start, dropouts and dropout
reasons, 4. funders, 5. compliance check, 6. dose check,
7. dietary intake data reported, 8. outcome comparability
and reproducibility and 9. similarity of most and least
exposed groups at baseline. The criteria for evaluating
these indicators were adapted from the Cochrane Hand-
book [29]. Based on these indicators, two reviewers
decided on the overall risk of bias.
Data synthesis
When necessary, units of measurement were converted
to a standard form to facilitate comparison across stud-
ies. If data were not presented in mean ± standard devi-
ation, they were converted into this format using
methods described in the Cochrane Handbook [29]. Tak-
ing into account that synthetic folic acid is more bio-
available than natural food folates, the amount of folic
acid from supplements was transformed into amount of
folate (multiplied by 1.7 to express it in Dietary Folate
Equivalents) [30]. When dietary intake was not provided,
the mean dietary folate intake (247 μg/day) from other
comparable studies investigating the relationship be-
tween folate intake and status [31] was included in the
calculation.
We calculated an intake-health regression coefficient
(β^ ) and its standard error (SE) for each individual study
[32]. The intake-health relationship was assumed to be
linear on the loge-loge scale (natural logarithm of intake
versus natural logarithm of the single health outcome).
This assumption is based upon our hypothesis that the
true intake-health curve for folate would follow a natural
logarithmic function, slowly growing to positive infinity
as x (intake) increases and rapidly going to negative
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infinity as x (intake) approaches 0. However, the true
shape of the relationships that we investigated is mostly
unknown. This shape of the curve (monotonic concave)
is a likely shape in biology. Therefore, we used this as-
sumption as a practical approximation. The basics of the
statistical model underlying the meta-analysis are
described in detail elsewhere [32].
Meta-analysis was carried out with Cochrane software,
Review Manager Version 5 (Cochrane Collaboration;
www.cochrane.org); we calculated the overall β^ using
random-effects model. A statistically significant result
indicated that the health outcome was indeed respond-
ing to supplementation. Levels of the heterogeneity were
noted (heterogeneity was considered significant where
P < 0.1 on the chi-square test, or I2 > 50%).
Results
Study inclusion
The flow diagram of the literature search for this sys-
tematic review is shown on Figure 1. Altogether 4067
hits were identified through the general electronic and
bibliographic searches. A total of 3784 titles appeared to
be inappropriate, only 283 described the population of
pregnant women and appeared to be potentially relevant
for the aim of this review. After abstract screening, 136
were collected as full-text papers and finally 8 publica-
tions fulfilled our inclusion criteria. One article con-
tained two different ethnic groups [25] and one article
contained two different interventions [24]. These data
were analyzed each as two separate studies, giving a total
of 10 substudies from 8 publications. The most common
reasons for exclusion were inappropriate study design,
combined intervention, i.e. multivitamin supplementa-
tion vs. placebo and not relevant study outcome.
The characteristics of the studies included in the
analysis are presented in Table 1. The age of pregnant
women was reported only in three studies [19,23,24];
one of them included pregnant adolescents [23]. Three
studies were carried out in Europe [24,28,33], two in
South America [19,23], two in Asia [26,27] and one
in Africa [25]. The supplement was synthetic folic
acid in most cases, subjects were treated with 5-
methyltetrahydrofolate (5-MTHF) in one study [24].
In those studies in which folic acid was used the inter-
vention group received folic acid together with an iron
supplement, while the control group received an iron
supplement alone. 5-MTHF versus placebo and 5-
MTHF together with fish oil versus fish oil were used
in the study by Klingler et al. [24].
Each included study represented high risk of bias (data
not shown). There was complete absence of data regard-
ing the method of randomization; the blinding was ad-
equate only in one study [23], and the reasons for
dropping out were reported in three studies only
[19,24,33].
Birth weight
Birth weight was the most frequently reported health
outcome, it was measured in 9 studies from 7 publica-
tions including 707 participants. Studies used a wide
range of supplementation doses from 0.25 mg to 5 mg
folic acid per day. The duration of supplementation var-
ied among studies from 12 to 22 weeks (Table 1).
Titles and abstracts retrieved 
from electronic, bibliographic 
and expert searches: 283
Titles and abstracts appeared 
potentially relevant and were 
collected as full texts: 136
Full papers included: 8
Birth weight: 7
Placental weight: 4
Length of gestation: 5
Titles and abstracts very unlikely to be 
relevant: 147
Papers excluded:
Not RCT, not adequate control group : 64
Combined intervention: 16
Non healthy subjects: 6
Other outcomes: 35
No population of interest: 2
Review: 4
Imprecise data: 1
Figure 1 Flow diagram of the systematic literature search.
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Folate supplementation resulted in significantly increased
birth weight in the intervention group compared to the
placebo group (P=0.001); the pooled effect estimate of the
relationship between total folate intake (dietary folate plus
folic acid/folate supplement) and birth weight was 0.03
(95% confidence interval (CI): 0.01, 0.05) (Figure 2). This
means that two-fold increase in folate intake corresponds
to a 1.02-fold (2β=20.03) higher birth weight, which is 2%
increase. The test for heterogeneity showed moderate
heterogeneity (I2=54%) among studies. There were insufficient
Figure 2 Response of birth weight to supplementation with folic acid or 5-methyltetrahydrofolate. Abbreviations: a,
5-methyltetrahydrofolate versus placebo; b, 5-methyltetrahydrofolate and with fish oil versus fish oil; c, Bantu women; d White women.
Table 1 Basic characteristics of included studies













N/A 65; 63a and
62; 52b
200 mg iron + 5 mg
FA/day
8620a; 8747b 16 wka and
12 wkb
birth weight
200 mg iron/day 120a; 247b
Iyengar
1971 [26]
India N/A 23; 26 60 mg iron + 300 μg
FA/day
757 18 wk birth weight
60 mg iron/day 247
Iyengar
1975 [27]
India N/A 98; 91 60 mg iron + 500 μg
FA/day
1097 16 wk birth weight;
placental weight
60 mg iron/day 247
Klingler
2006 [24]
Spain 18-40 y 16; 12 400 μg 5-MTHF/day 647 20 wk birth weight;
placental weight;
length of gestation
11; 16 placebo/day 247






Chile 26.8 ± 4.3 y
26.6 ± 5.3 y
75; 78 105 mg iron + 350 μg
FA/day
842 24 wk length of gestation
105 mg iron/day 247
Nogueira
2002 [23]
Brasil 13-18 y 15; 13 120 mg iron sulphate +
250 μg FA/day







Denmark N/A 20; 16 250 mg ferrofumarate +
5 mg FA/day
8747 17 wk birth weight;
placental weight;





France N/A 54; 54 iron + 350 μg FA/day 842 12 wk birth weight;
placental weight;
length of gestationiron/day 247
Abbreviations: a, data of Bantu women; b, data of White women; FA, folic acid; 5-MTHF, 5-methyltetrahydrofolate; N/A, data not available; *, expressed as Dietary
Folate Equivalents; **, supplements were administered from the second trimester to delivery in each study.
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studies to perform further analysis of different subgroups
according to supplement form, gestational age, dose or
duration.
Placental weight
Altogether 5 studies from 4 publications addressed the
association between folate intake and placental weight;
199 participants in the intervention group and 189 parti-
cipants in the control group were included. The duration
of supplementation ranged from 12 to 20 weeks. The
lowest supplementation dose was 0.35 mg, while the
highest supplementation dose was 5 mg folic acid per
day (Table 1).
As it can be seen on Figure 3, the meta-analysis
revealed no significant effect of total folate intake on pla-
cental weight (P=0.08), the pooled β^ was 0.04 (95% CI:
0.00, 0.09) with significant heterogeneity (I2=63%). The
low number of studies available did not allow further
analysis of different subgroups according to supplement
form, gestational age, dose or duration.
Length of gestation
Six studies from 5 publications involving 380 partici-
pants contained eligible data for the meta-analysis. Daily
dose of folic acid supplementation varied from 0.25 mg
to 5 mg, the duration was from 12 to 24 weeks
(Table 1).
The meta-analysis of the 6 RCTs available failed to
show any significant effect of increased folate intake on
length of gestation (P=0.77), the pooled β^ was 0.00 (95%
CI: -0.01, 0.01) (Figure 4). There was low heterogeneity
between studies (I2=40%). Like in the case of the previ-
ous health outcomes, we were not able to perform sub-
group analysis.
Discussion
Birth weight is one of the most important pregnancy
outcome parameters; it is strongly associated with infant
mortality during the first year of life and influences later
developmental processes as well [34]. Folate required for
growth reaches the maximal level in the last trimester
[35], because of rapid growth of the fetus and the utero-
placental system and fetal accumulation of folate stores.
Without sufficient folate intake, maternal plasma and
red blood cell (RBC) folate decreases from the fifth
month of pregnancy until several weeks after delivery
[36]. A recent prospective study has also shown that low
folate intake (< 187 μg/day) and low RBC folate status in
the late pregnancy increase the risk of small for gesta-
tional age (SGA) birth in an adolescent population [37].
Other studies reported positive association between
birth weight and maternal RBC folate status [13,38].
The present systematic review was aimed to
summarize available data on the role of folate status in
basic aspects of pregnancy outcome. Moreover, we
Figure 3 Response of placental weight to supplementation with folic acid or 5-methyltetrahydrofolate. Abbreviations: a,
5-methyltetrahydrofolate versus placebo; b, 5-methyltetrahydrofolate and with fish oil versus fish oil.
Figure 4 Response of length of gestation to supplementation with folic acid or 5-methyltetrahydrofolate. Abbreviations: a,
5-methyltetrahydrofolate versus placebo; b, 5-methyltetrahydrofolate and with fish oil versus fish oil.
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included 10 studies (from 8 published papers) into a
meta-analysis in order to assess whether there is any
dose–response relationship between folate intake and
birth weight, placental weight and length of gestation.
We applied base-e logarithmic transformation on fol-
ate intake and on the aforementioned pregnancy out-
come parameters. These transformations make it
possible to pool β^ values and report them as dose–
response relationship between intake and health. The
overall β^ represents the difference in the loge-trans-
formed predicted value of the given health outcome for
each one-unit difference in the loge-transformed value in
folate intake. The intervention was started from the sec-
ond trimester in all the included studies; therefore our
results allow inferences about supplementation during
pregnancy which differ substantially from periconcep-
tional folate supplementation.
Our results support the hypothesis that increased folate
intake after the first trimester is associated with higher
birth weight. The overall β^ was found to be 0.03 indicating
that a two-fold increase in folate intake corresponds to a
2% higher birth weight, which is a slight but significant in-
crease. Or to put it in another way, a neonate whose
mother has a folate intake of 500 μg per day is predicted
to have a birth weight that is 2% higher than a neonate
whose mother has a folate intake of 250 μg per day.
Placental weight is an important determinant of fetal
weight. It has been also demonstrated that placental
weight was significantly lower in SGA neonates com-
pared to appropriate for gestational age neonates of the
same birth weight [39]. Placental uptake of folate from
the maternal circulation is critical for adequate folate
supply to the developing fetus. Maternal folate is trans-
ferred against a concentration gradient to the fetus, the
net effect is a two-fold higher plasma folate level of the
neonates compared to the maternal plasma level at de-
livery [40]. Inadequate folate status during pregnancy
may be a risk factor of several adverse health outcomes,
such as fetal malformations and various placenta-related
diseases [41]. Moreover, low folate status results in ele-
vated plasma homocysteine level, which may increase
the risk of placental damage and dysfunction, disturbing
thereby oxygen and nutrient transport to the fetus [42].
In the present study we failed to detect any dose re-
sponse relationship between folate intake and placental
weight; our data did not show significantly elevated pla-
cental weight in treatment groups compared to placebo
groups (P=0.08). In contrast to the growth of the fetus,
the placenta grows rapidly in the first trimester and
reaches its full size during the second trimester [43],
therefore folate supplementation may have no further ef-
fect on placental weight in the later period of pregnancy.
A prospective study conducted on more than 2000
pregnant women demonstrated that low serum folate is
associated with nearly a double risk of preterm delivery
[44]. Scholl and colleagues have found similar degree of
risk for preterm delivery in women with low folate in-
take (≤ 240 μg per day) [45]. Still, like in the case of pla-
cental weight, we did not find significant effect of folate
supplementation on the length of gestation in the inter-
vention groups compared to placebo groups (P=0.77).
The strength of our meta-analysis is the inclusion of
RCTs. Ideally, RCTs should provide reliable data about
the effect of an intervention. Randomization allows us
to assume that changes in birth weight, placental
weight or length of gestation are definitely due to fol-
ate intervention. Other factors that might affect these
pregnancy outcomes would be expected to be distribu-
ted randomly between the intervention and control
groups.
The findings of this meta-analysis must be interpreted
in the light of certain limitations. First of all, the major-
ity of studies were conducted at least 30 years ago and,
according to our current standards, all of them had high
risk of bias. These uncertainties originate mainly from
the lack of methodological information in studies pub-
lished several decades ago: e.g. the laboratory parameters
of the included pregnant women and other potential
confounders, like smoking, alcohol consumption, mater-
nal BMI or sex of the infant were usually poorly
described. The substantial risk of bias increases the un-
certainty of our results and may lead to overestimation
or underestimation of the true treatment effect. Differ-
ences in supplement form, gestational age, dose or dur-
ation may explain the observed heterogeneity of
intervention effect; however, the low number of studies
included did not allow us to divide them into groups
and perform further subgroup analysis. Furthermore, it
must be taken into account that the potential reason of
the non-significant results of placental weight and length
of gestation analysis may be explained by the effect of
inadequate sample size. In addition, the studies included
in this meta-analysis evaluated approximately 700 birth
weights and 400 durations of pregnancy, which would
correspond to about 70 SGA birth weights and 40 pre-
term births in both interventional groups together. Thus
this study may be underpowered to make inferences
about those most important outcomes.
Conclusion
Our meta-analysis demonstrated significant dose–
response relationship between folate intake and birth
weight. However, the results indicated no evidence of
any effect of folate supplementation on placental weight
and length of gestation. The relative paucity of data that
we were able to collect into this systematic review indi-
cates that there is an urgent need to develop further
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high quality studies focusing on health outcomes of fol-
ate supplementation after the first trimester.
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